UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 10.

Schäfer, J; Young, J; Bernasconi, E; Ledergerber, B; Nicca, D; Calmy, A; Cavassini, M; Furrer, H; Battegay, M; Bucher, H C; Swiss HIV Cohort Study (2015). Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 16(1):3-14.

Young, J; Wang, Q; Fux, C A; Bernasconi, E; Furrer, H; Vernazza, P; Calmy, A; Cavassini, M; Weber, R; Battegay, M; Bucher, H C (2014). The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. HIV Medicine, 15(8):505-510.

Huber, M; Ledergerber, B; Sauter, R; Young, J; Fehr, J; Cusini, A; Battegay, M; Calmy, A; Orasch, C; Nicca, D; Bernasconi, E; Jaccard, R; Held, L; Weber, R (2012). Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians. HIV medicine, 13(7):387-397.

Røysland, K; Gran, J M; Ledergerber, B; von Wyl, V; Young, J; Aalen, O O (2011). Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. Statistics in Medicine, 30(24):2947-2958.

Young, J; Scherrer, A; Günthard, H; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 12(5):299-307.

Magenta, L; Dell-Kuster, S; Richter, W O; Young, J; Hasse, B; Flepp, M; Hirschel, B; Vernazza, P; Evison, J; Cavassini, M; Decosterd, L A; Bucher, H C; Bernasconi, E (2011). Lipid and lipoprotein profile in HIV-infected patients treated with Lopinavir/Ritonavir as a component of the first combination antiretroviral therapy. AIDS Research and Human Retroviruses, 27(5):525-533.

Young, J; Klein, M B; Ledergerber, B (2011). Noncirrhotic portal hypertension and didanosine: a re-analysis. Clinical Infectious Diseases, 52(1):154-155.

Serra, A L; Poster, D; Kistler, A D; Krauer, F; Raina, S; Young, J; Rentsch, K M; Spanaus, K S; Senn, O; Kristanto, P; Scheffel, H; Weishaupt, D; Wüthrich, R P (2010). Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. New England Journal of Medicine, 363(9):820-829.

Bucher, H C; Rickenbach, M; Young, J; Glass, T R; Vallet, Y; Bernasconi, E; Cavassini, M; Fux, C; Schiffer, V; Vernazza, P; Weber, R; Battegay, M (2010). Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. Antiviral Therapy, 15(1):31-40.

Young, J; Bucher, H C; Guenthard, H F; Rickenbach, M; Fux, C A; Hirschel, B; Cavassini, M; Vernazza, P; Bernasconi, E; Battegay, M (2009). Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antiviral Therapy, 14(6):771-779.

This list was generated on Mon Jul 24 16:21:47 2017 CEST.